Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 18, 2021 16:01 ET | Source: Kala Pharmaceuticals, Inc.

Kala Pharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WATERTOWN, Mass., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement...
November 15, 2021 08:47 ET | Source: Kala Pharmaceuticals, Inc.

Kala Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

-- Achieved $3.1 Million in Net Revenue in 3Q 2021 ---- EYSUVIS® Prescriptions Increased by 19% Compared to 2Q 2021-- Expanding Clinical-Stage Pipeline Through Acquisition of Combangio ---- Conference...
November 15, 2021 08:45 ET | Source: Kala Pharmaceuticals, Inc.

Kala Pharmaceuticals Acquires Combangio, Expanding its Pipeline with a Clinical-Stage Novel Biologic for the Treatment of Persistent Corneal Epithelial Defect (PCED) and other Rare Ocular Surface Diseases

-- KPI-012 is a novel secretome with a multifactorial mechanism of action for development in PCED and other orphan ocular surface diseases driven by impaired corneal healing ---- KPI-012 demonstrated...
November 15, 2021 07:00 ET | Source: Kala Pharmaceuticals, Inc.

Kala Pharmaceuticals Announces Time Change for Third Quarter 2021 Financial Results Conference Call

WATERTOWN, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization...
November 11, 2021 08:00 ET | Source: Kala Pharmaceuticals, Inc.

Kala Pharmaceuticals to Participate in Upcoming Investor Conferences in November 2021

WATERTOWN, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization...
November 08, 2021 16:01 ET | Source: Kala Pharmaceuticals, Inc.

Kala Pharmaceuticals to Report Third Quarter 2021 Financial Results and Host Conference Call

WATERTOWN, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization...
October 22, 2021 16:01 ET | Source: Kala Pharmaceuticals, Inc.

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass., Oct. 22, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement...
October 18, 2021 08:00 ET | Source: Kala Pharmaceuticals, Inc.

Kala Pharmaceuticals Announces Appointment of C. Daniel Myers to Board of Directors

WATERTOWN, Mass., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization...
September 21, 2021 16:01 ET | Source: Kala Pharmaceuticals, Inc.

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement...
September 07, 2021 08:00 ET | Source: Kala Pharmaceuticals, Inc.

Kala Pharmaceuticals to Present at Upcoming Investor Conferences in September 2021

WATERTOWN, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and...